8-K: Autonomix Medical Secures $5M in Private Placement

Autonomix Medical, Inc. completed a private placement raising approximately $5.0 million through the sale of pre-funded and Series C common stock warrants to an institutional investor.

Summary

• Autonomix Medical, Inc. (AMIX) entered into a Securities Purchase Agreement with an institutional investor on November 18, 2025, for a private placement.
• The company sold pre-funded warrants to purchase 4,501,666 shares of common stock and Series C warrants to purchase up to 9,003,332 shares of common stock.
• The combined purchase price for one pre-funded warrant and accompanying common warrants was $1.1097.
• Each pre-funded warrant is exercisable at $0.001 per share and expires upon full exercise.
• Each Series C warrant is exercisable at $0.8607 per share and expires five and a half years from the initial exercise date.
• The closing of the offering occurred on November 19, 2025, generating approximately $5.0 million in gross proceeds before deducting fees and expenses.
• Net proceeds are intended for working capital and general corporate purposes.
• The company engaged Maxim Group LLC as the exclusive placement agent, agreeing to pay a cash fee of up to 8% of gross proceeds and reimburse expenses up to $50,000.
• Autonomix Medical agreed to file a registration statement for the resale of the underlying common stock within 20 days and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days if reviewed by the SEC).
• The company is subject to certain lock-up provisions, prohibiting the issuance of equity securities for 60 days post-registration statement effectiveness, with exceptions.
• A prohibition on Variable Rate Transactions is in place for six months after the registration statement's effective date, with an exception for at-the-market sales above $1.1107 per share after 60 days.

Sentiment

Score: 6

Explanation: The filing indicates a successful capital raise, which is positive for funding operations. However, the significant potential for future dilution from the warrants and the associated fees temper the overall positive sentiment. The company's explicit acknowledgment of substantial dilution is a notable point.

Positives

• Successfully raised approximately $5.0 million in gross proceeds, providing capital for working capital and general corporate purposes.
• The pre-funded warrants have a nominal exercise price of $0.001, indicating a significant portion of the capital was received upfront.
• The company has secured a commitment to file a registration statement for the resale of the underlying shares, which can provide liquidity for investors.

Negatives

• The offering involves the issuance of warrants, which will lead to future dilution upon exercise.
• Placement Agent fees of up to 8% of gross proceeds and up to $50,000 in expenses will reduce the net proceeds received by the company.
• The company acknowledges that the issuance of securities may result in substantial dilution of outstanding common stock.
• Restrictions on subsequent equity sales and variable rate transactions could limit future financing flexibility for a period.

Risks

• Future dilution from the exercise of pre-funded and Series C warrants.
• Potential negative impact on the market price of common stock due to hedging activities by purchasers, including short sales.
• Failure to timely file or achieve effectiveness of the registration statement could result in liquidated damages payable to warrant holders.
• Failure to maintain current public information requirements under Rule 144 could also result in liquidated damages.
• The company's ability to renew existing insurance coverage or obtain similar coverage without a significant cost increase is a risk.
• Potential for legal actions or investigations related to compliance with various laws (e.g., environmental, labor, FDA, data privacy) if not in compliance, which could have a Material Adverse Effect.

Future Outlook

The company intends to use the net proceeds from this offering to fund working capital and general corporate purposes. It also commits to filing a registration statement for the resale of the underlying shares and maintaining its listing on the Nasdaq Stock Market LLC.

Management Comments

• The company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions.
• The company confirms that its obligations under the Transaction Documents are unconditional and absolute, not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution.

Industry Context

This capital raise provides Autonomix Medical with additional funding, which is crucial for medical device and biotechnology companies that typically require significant capital for R&D, clinical trials, and commercialization efforts. The use of warrants is a common financing mechanism in this sector, often used to attract investors by offering potential upside while providing immediate capital to the company.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience dilution upon the exercise of the warrants. The company explicitly acknowledges that this dilution may be substantial. The 60-day lock-up on new equity issuances (with exceptions) provides some short-term stability, but the longer-term variable rate transaction prohibition could impact future financing flexibility.
• **Investors (Purchasers of Warrants)**: The institutional investor gains the right to acquire a significant number of common shares at specified exercise prices, with pre-funded warrants offering immediate exercisability at a nominal cost. They also benefit from registration rights and liquidated damages clauses for non-compliance, providing downside protection and liquidity pathways.
• **Employees**: The capital raise provides funding for general corporate purposes, which can support ongoing operations and potentially job security, but no direct impact on employee compensation or benefits is mentioned.
• **Creditors**: The additional capital improves the company's liquidity and financial position, potentially reducing credit risk, as proceeds are for working capital and general corporate purposes.

Next Steps

• File a registration statement for the resale of the common stock underlying the warrants within 20 calendar days from November 18, 2025.
• Use commercially reasonable best efforts to cause the registration statement to be declared effective by the SEC within 60 calendar days (or 90 days if reviewed).
• Maintain the listing or quotation of the Common Stock on its Trading Market and apply to list all Shares and Warrant Shares.
• Comply with lock-up provisions and variable rate transaction prohibitions for specified periods.

Key Dates

Recommendation

The capital raise provides essential funding for Autonomix Medical's operations and general corporate purposes, which is a positive for the company's stability and ability to pursue its strategic objectives. However, the significant potential for future dilution from the warrants, coupled with the fees paid to the placement agent, introduces a notable overhang on the stock. While the company has secured funding, the dilutive nature of the transaction and the associated costs suggest a 'hold' recommendation, as investors should monitor the impact of warrant exercises and the company's ability to effectively utilize the capital to drive value before considering further investment.

Keywords

Private Placement, Warrants, Pre-Funded Warrants, Series C Warrants, Capital Raise, Equity Financing, Dilution, SEC Filing, Form 8-K, Autonomix Medical, AMIX, Maxim Group LLC